Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > CRDF Cardiff Oncology > Main Composition
CRDF Cardiff Oncology
1.520
-0.070-4.40%
All
YOY
Do not show
Business Unit:USD
nameYOYOperating income%
Royalty revenues--359K100.00%
Region Unit:USD
nameYOYOperating income%
U.S.--359K100.00%
Company Overview More
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
CEO: Dr. Mark Erlander, PhD
Market: NASDAQ
Listing Date: 07/31/2003
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist